Mr. Clay siegall Gives Hope to Cancer Patient

Cancer is a dreaded disease, and many people know it as a death sentence. However, it is one thing to think about cancer as deadly, and it’s another thing to finds the solution regarding awareness and treatment. These days, many companies have intensified their efforts in the search for a lasting cure for the disease.Talking of intensive research on cancer, Seattle Genetics, under the leadership of one Clay Siegall has come out with exciting innovations regarding cancer therapy.

According to engadget.com, Jesse Boskoff, the author describes Seattle Genetics CEO Mr. Clay Siegall as a man who is so passionate about improving the lives of cancer patients. He goes on to touch on how the company’s stock price has tripled in the recent past, attributing it to the fact that the enterprise role in cancer therapy is growing.

Other than him being the company’s CEO, Mr. Clay is also a member of the chairman of the board at Seattle Genetics. Since 2002, he has served as the Chief Executive Officer of the firm. He came in as the co-founder of the company in 1998 and since then, for almost two decades now, he has continued to put his best foot forward and lead the company in doing top quality cancer research.

Mr. Clay formally worked at Bristol-Myers Squibb Pharmaceutical Research Institute, where he started his career. Here, he was the Senior Research Investigator. He later got promoted to Principal Scientist, and afterward became a Staff and Biotechnology person at the National Cancer Institute. He worked for some time before he became the co-founder and launched the Seattle Genetics company.

As the president and CEO of Seattle Genetics, Clay has entered into a myriad of strategic licenses for its ADC technology. Examples include Genentech (Roche), AbbVie, GlaxoSmithKline, and Pfizer. To this day, these grants have generated an upward of $350 million. Mr. Clay has also been actively involved in the company’s capital raising activities in which he has helped raise more than $1.2 billion through the public and private financing.

He holds a Ph.D. in genetics from George Washington University and also a B.S. in Zoology, which he received from the University of Maryland. He has received various awards such as the Pacific Northwest Ernst & Young Entrepreneur of the Year 2012 and also University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences 2013.